TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06280534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug XT1061 capsules and placebo,Single dose group
Description: Eight people took capsules of the test drug XT1061 and two people took a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug XT1061 capsules and placebo，Multiple dosing group
Description: D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug XT1061 capsules and placebo，Food Impact Group
Description: Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
Study: NCT06421272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP-based emotion recognition intervention
Description: ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: APP-based memory intervention
Description: ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
Study: NCT05400629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
Study: NCT05700253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation
Description: Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Injection
Description: Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
Study: NCT04880642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21
Study: NCT05485493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Solution Focused Short-Term Group Counseling
Description: Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: healthy nutrition education
Description: 60-minute single session healthy eating training
Study: NCT05295706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterfactual Intervention
Description: The intervention occurs during the third study visit. This is a counterfactual intervention, which will involve asking the subjects to think of an alternative reality that might have been based on the concurrency of their glucose readings and the meals they ate.
Study: NCT06186349

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
Study: NCT04880642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05117580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine lifestyle guidance
Description: Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
Study: NCT06227429

Intervention type: DRUG
Intervention: Nitisinone
Description: According to prescription
Study: NCT05585021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wonderlab Kids instant probiotics
Description: During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Instant probiotic placebo
Description: Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period.
Study: NCT05426226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture
Description: using laser acupuncture device on sleep acupoints during sleep

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham device
Description: using sham device on sleep acupoints during sleep
Study: NCT05978752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices
Description: For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices
Description: For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)
Description: For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
Study: NCT05432635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR CMV-specific T-lymphocytes
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autoHSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study: NCT05641987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Workplace Participatory Program
Description: The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Workplace Participatory Program
Description: The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
Study: NCT04573218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 250 mg OPP
Description: 250 mg Oil Palm Phenolics
Study: NCT05086874

Intervention type: OTHER
Intervention: butylphthalide
Description: Observational only and no predesigned interventions in this study
Study: NCT05025722

Intervention type: OTHER
Intervention: Non Interventional
Description: This is an observational study.
Study: NCT05432635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative Conditioning
Description: Given standard conditioning regimen
Study: NCT05593419

Intervention type: DEVICE
Intervention: TIIC signature
Description: Collect tumor tissue of 300 gastric cancer patients at treatment baseline, samples will be transferred to central lab to detect the density and spatial proximity of certain immune cells infiltrated in tumor by multi complex immunohistochemistry, and evaluate patients' TIIC signature.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastaticorgan ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT05808478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC + Eye Tracking
Description: The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AAC
Description: Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
Study: NCT05025722

Intervention type: OTHER
Intervention: Non Interventional
Description: This is an observational study.

Intervention type: OTHER
Intervention: Non Interventional
Description: This is an observational study.
Study: NCT05015283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The laparoscopic One-anastomosis gastric bypass will consist of:
Description: gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The laparoscopic Roux-en-Y gastric bypass will consist of:
Description: the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
Study: NCT05741827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle intervention focusing on diet and physical activity
Study: NCT04739631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile needles to insert to the acupuncture point

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: minimal acupuncture
Description: The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
Study: NCT04500834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Metal Panel T.R.U.E. Test
Description: Diagnostic patch test
Study: NCT05676814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pecto-intercostal Fascial Block (PIFB)
Description: PIFB done with bupivacaine and epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIFB with adjuvants
Description: PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
Study: NCT06176729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin, Rituximab, Lenalidomide
Description: polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
Study: NCT04979403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
Study: NCT06329882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyclin
Description: Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
Study: NCT05653115

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery
Study: NCT04541394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MolecuLight
Description: MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
Study: NCT05502120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with Vie-Scope laryngoscope
Description: Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy with Macintosh blade laryngoscope
Description: Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
Study: NCT06421194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]
Description: Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]
Description: Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]
Description: Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]
Description: Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
Study: NCT05761158

Intervention type: OTHER
Intervention: questionnaire
Description: patients are asked to complete a questionnaire
Study: NCT05158543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented training (moderate intensity)
Description: In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented training (high intensity)
Description: In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
Study: NCT04900961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
Study: NCT05320640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）
Description: Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
Study: NCT06254456

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End expiratory occlusion test
Description: Fluid responsiveness test
Study: NCT05389345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function training
Description: The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Executive function training
Description: The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
Study: NCT05423028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided nerve hydrodissection
Description: Peri- median nerve injection for hydrorelease and decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve hydrodissection
Description: Peri- median nerve injection for hydrorelease and decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve hydrodissection
Description: Peri- median nerve injection for hydrorelease and decompression
Study: NCT04983186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor and smartphone application
Description: Empatica E4 wearable sensor and custom-made headache smartphone application
Study: NCT06291714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GDT-based hemodynamic management based on Clearsight device
Description: Intraoperative use of a HPI-guided hemodynamic goal-directed protocol based on the non-invasive measurement of HPI (Clearsight system)
Study: NCT05858645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deucravacitinib
Description: Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
Study: NCT06072573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap (AP707)
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.